Clinical trial
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With…
NCT00385255 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00385255 |
|---|---|
| Title | Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults |
| Official title | A Study to Evaluate Immunogenicity and Safety of Boostrix When Co-administered With Fluarix in Subjects 19 Years of Age and Older |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acellular Pertussis, Diphtheria, Tetanus |
| Intervention type | Biological |
| Interventions | Fluarix®, Boostrix® |
| Enrollment | 1,726 |
| Start date | Oct 23, 2006 |
| Primary completion | Feb 28, 2007 |
| Completion | Feb 28, 2007 |
| First posted | Oct 9, 2006 |
| Last update posted | Jun 10, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: